| abstract |
A pharmaceutical formulation of a β2 integrin agonist comprising an effective amount of a β2 integrin agonist and a pharmaceutically acceptable carrier. A method of activating β2 integrin by interacting β2 integrin with a β2 integrin agonist. A method of treating a patient by administering an effective amount of a β2 integrin agonist and activating the β2 integrin. A method of treating inflammation by administering a β2 integrin agonist to a patient with inflammation, activating β2 integrin and reducing inflammation. Treat and / or prevent renal ischemia-reperfusion (I / R) injury, reduce patient damage due to stent insertion, conduct assays for identification of small molecule modulators of β2 integrin, detect patient disease And how to improve the overall health of the patient. [Selection figure] None |